Biogen is progressing key clinical-stage programs, including its acquisition of Alcyone Therapeutics for $85 million to enhance RNA drug delivery via implantable devices. The company also celebrated groundbreaking for its new Kendall Square headquarters, marking a renewed commitment to innovation amidst a challenging biotech funding environment. Concurrently, Arsenal Biosciences reduced its workforce by half to concentrate resources, reflecting broader strategic pivots within the cell therapy sector.